- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Govt excludes anti-parasitic drug Ivermectin from Covid-19 treatment protocol
A government official said, "It has been decided not to recommend ivermectin medicine in the National Clinical Management Protocol for Covid19 as there is not enough safety and efficacy evidence as per the randomized trials held across the world."
New Delhi: The Union Health Ministry has decided not to include ivermectin medicine (antiparasitic drug) in the National Clinical Management Protocol for Covid-19 for the treatment of virus-infected patients.
The move comes after the Central government's National Task Force for Covid-19 and the health ministry's Joint Monitoring Group (JGM) chaired a meeting on Thursday to discuss if the anti-parasitic drug should be included in the national treatment guidelines or not.
A government official said, "Many states, for example--Uttar Pradesh, are utilizing the drug as off label for treatment purpose and also for prophylaxis use against Covid-19. Now, it has been decided not to recommend ivermectin medicine in the National Clinical Management Protocol for Covid-19 as there is not enough safety and efficacy evidence as per the randomized trials held across the world."
Ivermectin medicine is an inexpensive and safe drug that is used for the treatment of intestinational parasites and scabies.
Read also: CSIR-Centre developing proof of concept for Covid vaccine as part of Aurobindo Pharma pact
In the fight against Covid-19, the Union Health Ministry has approved the use of several drugs in the treatment of coronavirus with subject to conditions in the Clinical Management Protocol for Covid-19.
The Central government has already recommended the use of--remdesivir under "investigational therapies" only for restricted emergency use in moderate Covid-19 cases. Another drug called--tocilizumab is being used as off-label for the treatment of Covid patients. Meanwhile, anti-malaria drug hydroxychloroquine (HCQ) is being utilized in patients during the initial stage of infection.
covid drugremdesivirtocilizumabhydroxychloroquinemohfwhcqivermectinunion health ministerhealth ministrydr harsh vardhan
Source : ANIRuchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story